{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:23:29Z","timestamp":1762842209174,"version":"build-2065373602"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100334","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T15:11:18Z","timestamp":1613401878000},"page":"100334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions"],"prefix":"10.1016","volume":"27","author":[{"given":"Alessandro","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctarc.2021.100334_bib0001","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100334_bib0002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.21873\/cgp.20203","article-title":"Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives","volume":"17","author":"Rizzo","year":"2020","journal-title":"Cancer Genomics Proteomics"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100334_bib0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0004","doi-asserted-by":"crossref","unstructured":"Rizzo A., Ricci A.D., Brandi G. Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer. Hepatobiliary Pancreat Dis Int. 2020 Dec 9:S1499-3872(20)30248-4. doi: 10.1016\/j.hbpd.2020.12.010.","DOI":"10.1016\/j.hbpd.2020.12.010"},{"issue":"9935","key":"10.1016\/j.ctarc.2021.100334_bib0005","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2021.100334_bib0006","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cancers12082308","article-title":"Evolution of the experimental models of cholangiocarcinoma","volume":"12","author":"Massa","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100334_bib0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5604\/16652681.1226927","article-title":"Intrahepatic, perihilar and distal cholangiocarcinoma: management and outcomes","volume":"16","author":"Waseem","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0008","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2021.100334_bib0009","doi-asserted-by":"crossref","unstructured":"Banales J.M., Marin J.J.G., Lamarca A., et\u00a0al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020; 10.1038\/s41575-020-0310-z.","DOI":"10.1038\/s41575-020-0310-z"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100334_bib0010","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 Clinical Trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0011","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling","volume":"35","author":"Bridgewater","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100334_bib0012","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2016.08.013","article-title":"Molecular characteristics of biliary tract cancer","volume":"107","author":"Sohal","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0014","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100334_bib0015","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/liv.13517","article-title":"Risk estimation for biliary tract cancer: development and validation of a prognostic score","volume":"37","author":"Schweitzer","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100334_bib0016","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/ags3.12266","article-title":"Essential updates to the surgical treatment of biliary tract cancer","volume":"3","author":"Matsukuma","year":"2019","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.ctarc.2021.100334_bib0017","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctarc.2021.100334_bib0018","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100334_bib0019","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100334_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001042","article-title":"The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?","volume":"5","author":"Ricci","year":"2020","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100334_bib0021","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100334_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820948047","article-title":"Immunotherapy in Biliary Tract cancer: worthy of a second look","volume":"27","author":"Ricci","year":"2020","journal-title":"Cancer Control"},{"key":"10.1016\/j.ctarc.2021.100334_bib0023","article-title":"Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives","volume":"13","author":"Sanoyan","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0024","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ctrv.2008.11.009","article-title":"Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions","volume":"35","author":"Anderson","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctarc.2021.100334_bib0025","first-page":"1","article-title":"BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care","volume":"18","author":"Rizzo","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100334_bib0026","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3390\/cancers12051237","article-title":"Biliary tract cancer: current medical treatment strategies","volume":"12","author":"Oneda","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100334_bib0027","doi-asserted-by":"crossref","first-page":"64","DOI":"10.21037\/cco.2016.08.05","article-title":"Adjuvant therapy for resected biliary tract cancer: a review","volume":"5","author":"Doherty","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctarc.2021.100334_bib0028","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100334_bib0029","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1470-2045(19)30022-1","article-title":"Adjuvant capecitabine in biliary tract cancer: a standard option?","volume":"20","author":"Malka","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100334_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21037\/cco.2019.07.02","article-title":"Adjuvant therapy for resected gallbladder cancer","volume":"8","author":"Suzuki","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0031","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3390\/cancers12082190","article-title":"Molecular and immunological characterization of biliary tract cancers: a paradigm shift towards a personalized medicine","volume":"12","author":"Malenica","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100334_bib0032","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/cncr.11699","article-title":"Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies","volume":"98","author":"Jarnagin","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100334_bib0033","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00000658-200203000-00011","article-title":"Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients","volume":"235","author":"Weber","year":"2002","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctarc.2021.100334_bib0034","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00268-005-7763-7","article-title":"Clinicopathological factors pre- dicting long-term overall survival after hepatectomy for peripheral cholangio- carcinoma","volume":"29","author":"Jan","year":"2005","journal-title":"World J Surg"},{"key":"10.1016\/j.ctarc.2021.100334_bib0035","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00535-006-1877-z","article-title":"Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery","volume":"41","author":"Miwa","year":"2006","journal-title":"J Gastroenterol"},{"issue":"31","key":"10.1016\/j.ctarc.2021.100334_bib0036","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2012.41.5984","article-title":"Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy","volume":"20","author":"Wang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0037","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jso.24856","article-title":"The impact of perioperative CA19-9 change on the survival and recurrence patterns after adjuvant chemor- adiotherapy in resectable extrahepatic cholangiocarcinoma","volume":"117","author":"Kim","year":"2018","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100334_bib0038","doi-asserted-by":"crossref","first-page":"v65","DOI":"10.1093\/annonc\/mdq167","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Eckel","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0039","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0360-3016(99)00472-1","article-title":"Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma","volume":"46","author":"Todoroki","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100334_bib0040","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0360-3016(02)02952-8","article-title":"Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer","volume":"54","author":"Kim","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctarc.2021.100334_bib0041","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2011.05.003","article-title":"Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies","volume":"38","author":"Bonet","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctarc.2021.100334_bib0042","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.ijrobp.2008.09.017","article-title":"Radiotherapy is associated with im- proved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas","volume":"74","author":"Shinohara","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctarc.2021.100334_bib0043","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100334_bib0044","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100334_bib0045","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/SLA.0000000000002385","article-title":"Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy","volume":"266","author":"Kasumova","year":"2017","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100334_bib0046","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JOP.18.00683","article-title":"Adjuvant therapy for biliary tract cancers: desperately seeking data","volume":"14","author":"Tran Cao","year":"2018","journal-title":"J Oncol Pract"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100334_bib0047","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a Randomized Phase III Study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100334_bib0048","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Bile Duct Cancer Adjuvant Trial (BCAT) Study Group. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100334_bib0049","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100334_bib0050","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100334_bib0051","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-020-00767-3","article-title":"New treatment options for advanced biliary tract cancer","volume":"21","author":"Mizrahi","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100334_bib0052","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","article-title":"Systemic therapies for intrahepatic cholangiocarcinoma","volume":"72","author":"Kelley","year":"2020","journal-title":"J Hepatol"},{"issue":"33","key":"10.1016\/j.ctarc.2021.100334_bib0053","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: a Phase II Intergroup Trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"20","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100334_bib0054","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.canlet.2015.09.008","article-title":"Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management","volume":"379","author":"Zhang","year":"2016","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100334_bib0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jjco\/hyy082","article-title":"New developments in systemic therapy for advanced biliary tract cancer","volume":"48","author":"Morizane","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102975","article-title":"Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials","volume":"151","author":"Belkouz","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100334_bib0057","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/cancers12082039","article-title":"Targeted therapies in advanced biliary tract cancer: an evolving paradigm","volume":"12","author":"Chakrabarti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100334_bib0058","doi-asserted-by":"crossref","unstructured":"Zhao D.Y., Lim K.H. Current biologics for treatment of biliary tract cancers. J Gastrointest Oncol. Published online 2017. doi:10.21037\/jgo.2017.05.04.","DOI":"10.21037\/jgo.2017.05.04"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100334_bib0059","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JOP.18.00682","article-title":"Adjuvant therapy for biliary tract cancers: new evidence to resolve old questions","volume":"14","author":"Cloyd","year":"2018","journal-title":"J Oncol Pract"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100334_bib0060","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in Biliary Tract Cancer","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100334_bib0061","unstructured":"Abou-Alfa G.K., Sahai V., Hollebecque A., et\u00a0al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020. pii: S1470-2045(20)30109-1."},{"key":"10.1016\/j.ctarc.2021.100334_bib0062","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100334_bib0063","doi-asserted-by":"crossref","first-page":"E3404","DOI":"10.3390\/cancers12113404","article-title":"A perspective on cell therapy and cancer vaccine in Biliary Tract Cancers (BTCs)","volume":"12","author":"Han","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100334_bib0064","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctarc.2021.100334_bib0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2021.100334_bib0066","article-title":"Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy","volume":"29","author":"Rizzo","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0067","article-title":"Emerging biomarkers in urothelial carcinoma: challenges and opportunities","volume":"25","author":"Andreatos","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ctarc.2021.100334_bib0068","article-title":"Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma","volume":"23","author":"Gulati","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"14","key":"10.1016\/j.ctarc.2021.100334_bib0069","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.12998\/wjcc.v7.i14.1753","article-title":"Current status of the adjuvant therapy in uterine sarcoma: a literature review","volume":"7","author":"Rizzo","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ctarc.2021.100334_bib0070","doi-asserted-by":"crossref","unstructured":"Herbst R.S., Baas P., Kim D.W., et\u00a0al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. Published online 2016. doi:10.1016\/S0140-6736(15)01281-7.","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"10.1016\/j.ctarc.2021.100334_bib0071","doi-asserted-by":"crossref","unstructured":"Borghaei H., Paz-Ares L., Horn L., et\u00a0al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. Published online 2015. doi:10.1056\/NEJMoa1507643.","DOI":"10.1056\/NEJMoa1507643"},{"key":"10.1016\/j.ctarc.2021.100334_bib0072","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1245\/s10434-016-5101-y","article-title":"Program Death 1 Immune Checkpoint and Tumor Microenvironment: implications for Patients With Intrahepatic Cholangiocarcinoma","volume":"23","author":"Gani","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100334_bib0073","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100334_bib0074","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/COC.0b013e31829e19fb","article-title":"Outcome of adjuvant therapy in biliary tract cancers","volume":"38","author":"McNamara","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100334_bib0075","first-page":"1","article-title":"Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives","volume":"25","author":"Rizzo","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100334_bib0076","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729241","article-title":"Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma","volume":"24","author":"Chun","year":"2017","journal-title":"Cancer Control"},{"key":"10.1016\/j.ctarc.2021.100334_bib0077","doi-asserted-by":"crossref","first-page":"10871","DOI":"10.2147\/CMAR.S224583","article-title":"The significance of adjuvant therapy for extrahepatic cholangiocarcinoma after surgery","volume":"11","author":"Wang","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100334_bib0078","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.hbpd.2018.11.001","article-title":"The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: a meta-analysis and systematic review","volume":"18","author":"Wang","year":"2019","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.ctarc.2021.100334_bib0079","first-page":"1","article-title":"Recent advances of immunotherapy for biliary tract cancer","volume":"8","author":"Rizzo","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100334_bib0080","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/hpb.12441","article-title":"Intrahepatic cholangiocarcinoma: expert consensus statement.","volume":"17","author":"Weber","year":"2015","journal-title":"HPB (Oxford)"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:20:57Z","timestamp":1762842057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":80,"alternative-id":["S2468294221000332"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100334","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100334"}}